FC:AI · OPEN SOURCE ME · CANCER PROFILE

# Russ Read-Barrow

DOB 2 July 1982 · Bath, UK · Treated at The Bath Clinic, Claverton Down, Bath
No known drug allergies · WHO performance status 0

CORRECT AS AT
17 SEPTEMBER 2026
Check the QR code for the latest version

**ON TREATMENT** Cycle 3 of FOLFIRI + cetuximab rechallenge — Cycle 4 due 30 Sep 2026 · CT after Cycle 5

| STAGE | CEA | CYCLE | WHO PS | PD-L1 |
|---|---|---|---|---|
| IV | 50.9 | 3 | 0 | <1% |
| Metastatic | ug/L · 14 Sep 26 · ref 0–5.2 | of this block · 15th FOLFIRI+cetux overall | Fully active · 24 Aug 26 | TPS · negative |

## DIAGNOSIS

**Moderately differentiated adenocarcinoma, rectosigmoid colon**

ypT4a ypN1b (3/24 nodes) M1a V+ · Treatment began Dec 2021; primary resected Mar 2022

**Where it is now:** Lungs · mediastinal lymph nodes · liver segment VII (new, Jul 2026)

- Smouldering myeloma (diagnosed end of 2021, under haematology surveillance)
- Gilbert's syndrome (can raise bilirubin)

## MOLECULAR PROFILE

EXACTA report, 1 Sep 2025

KRAS/NRAS wild-type · BRAF wild-type · pMMR / MSS · HER2 IHC 0 · TMB-low · 3 Mut/Mb · PD-L1 <1% (22C3, 28-8)

**APC** p.S1415Rfs*4 — PATHOGENIC
Frameshift · tissue MAF 8.5% · cfDNA 0.62%

**TP53** p.R342* — PATHOGENIC
Nonsense · tissue MAF 9.21%

**PTEN** reported, not specified — TO CONFIRM
Named in my oncology letters. Exact variant, allele fraction and classification not in my records yet

VUS: RUNX1T1, FANCM, CIC, BCR, CYP2D6. Exploratory (Astron/ICC): MTOR and VEGFR1/2 protein positivity, HMGB1 overexpression

## CURRENT TREATMENT

14 days cycles

**FOLFIRI + cetuximab (rechallenge, 3rd block)**

| C1 | C2 | C3 | C4 | C5 |
|---|---|---|---|---|
| 19 Aug 26 | 2 Sep 26 | 16 Sep 26 | 30 Sep 26 | TBC |

| | | |
|---|---|---|
| Cetuximab | 500 mg/m² | 1000 mg |
| Irinotecan | 180 mg/m² | 400 mg |
| 5-FU bolus | 400 mg/m² | 900 mg |
| 5-FU infusion (46h) | 2400 mg/m² | 5000 mg |
| Folinic acid | | 350 mg |

Full doses, dose-banded · BSA 2.08 m² (84.5 kg, 185 cm, 16 Sep 26)

Plan: 8–12 weeks, then consider maintenance 5-FU + cetuximab if response is good. CT after Cycle 5.

## CEA TUMOUR MARKER

ug/L




FOLFIRI + cetuximab blocks · 19 readings, Apr 2025 – Sep 2026

## KEY BLOODS

14 Sep 2026

| | | | |
|---|---|---|---|
| Haemoglobin | 133 g/L | White cells | 6.64 ×10⁹/L |
| Neutrophils | 3.99 ×10⁹/L | Platelets | 289 ×10⁹/L |
| ALT | 26 U/L | AST | 26 U/L |
| ALP | 179 U/L H | Bilirubin | 13 µmol/L |
| Albumin | 43 g/L | Globulin | 37 g/L H |
| Creatinine | 75 µmol/L | Magnesium | 0.89 mmol/L |
| Potassium | 4.2 mmol/L | GGT | 22 U/L |

## LATEST IMAGING

**23 Jul 2026 · CT chest, abdomen & pelvis**

Progression above and below the diaphragm, and a new liver metastasis

CT report, 23 Jul 2026, compared with May 2026

**Before that:** 12 May 2026, CT chest, abdomen & pelvis: "Good response to treatment within the mediastinum and lungs."

## TREATMENT HISTORY

| | |
|---|---|
| Dec 21–Feb 22 | Neoadjuvant XELOX ×4 · good partial response |
| Mar–Oct 22 | Primary resected · liver met resected (R0) · adjuvant CAPOX |
| Oct 22–Apr 23 | Lung mets appear, progress · SABR 55 Gy/5 |
| Jun & Aug 24 | Lung ablations (1 left, then 1 left + 4 right) |
| Feb 25 | EBUS confirms mediastinal nodal disease |
| Apr–Jul 25 | FOLFIRI + cetuximab ×6 · good partial response |
| Feb–May 26 | Rechallenge ×6 · excellent partial response |
| Jul–Aug 26 | Progression during the break · FOLFIRI + cetuximab restarted 19 Aug |

## MEDICATION & PROTOCOL

Current meds · 17 Sep

| | |
|---|---|
| CHEMO DAY | Standard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after |
| SUPPORTIVE | Dexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN |
| OTHER | Citalopram 30 mg (breakfast) · melatonin 60 mg (evening) · loratadine 10 mg |
| PAUSED | Mistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice |

## WHAT I'M LOOKING INTO

- BNT314 + pumitamig (BNT327) + chemo · MSS/pMMR mCRC
- Botensilimab + balstilimab · pre-treated MSS CRC
- WNT/β-catenin-targeted: ST316 (NCT05848739, phase 1–2) · tegavivint

Know this profile? Patients with similar disease, oncologists, scientists and geneticists — I want to hear from you. Not generic advice, please.

**Live, fuller version:** fcancerwith.ai/open-source-me · **Contact:** russreadbarrow@gmail.com

Compiled by me from my own clinical records (organised in NotebookLM, checked against the source documents). This is my data, shared openly. It is not medical advice. Version 2026-09-17.